Search

Search Results

1. Recent progress in the management of pediatric chronic myeloid leukemia

   Chronic myeloid leukemia (CML) is a rare myeloproliferative disease in children. The primary cause of CML is the chimeric BCR::ABL1 gene in...

   Haruko Shima, Hiroyuki Shimada in International Journal of Hematology

   Article 27 December 2022
   

2. Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations

   Treatment of chronic myeloid leukemia has improved significantly with the introduction of tyrosine kinase inhibitors (TKIs), and treatment guidelines...

   Stephanie Sembill, Maria Ampatzidou, ... Markus Metzler in Leukemia

   Article Open access 27 January 2023
   

3. Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia

   Response to tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML) is monitored by quantification of BCR::ABL1 ...

   Christian Volz, Thomas Zerjatke, ... Markus Metzler in Scientific Reports

   Article Open access 24 October 2023
   

4. Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course

   The clinical presentation of chronic myeloid leukemia (CML) at diagnosis differs in children compared to adults. At younger age, anemia appears to...

   Fanny Delehaye, Jérémie Rouger, ... Frédéric Millot in Annals of Hematology

   Article 12 November 2022
   

5. Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study

   Poor-risk (PR) cytogenetic/molecular abnormalities generally direct pediatric patients with acute myeloid leukemia (AML) to allogeneic hematopoietic...

   Akshay Sharma, Jacques-Emmanuel Galimard, ... Selim Corbacioglu in Bone Marrow Transplantation

   Article 15 January 2024
   

6. BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach

   Purpose of Review

   The purpose of this review is to summarize the most updated treatment recommendations for pediatric CML, and to discuss current...

   Jenna M. Menger, Ryan S. Sathianathen, ... Nobuko Hijiya in Current Oncology Reports

   Article 10 February 2024

7. Treatment-Free Remission in Chronic Myeloid Leukemia

   Over the last decade, a medically supervised trial of tyrosine kinase inhibitor (TKI) discontinuation has become an important option for patients...

   Naranie Shanmuganathan, David M. Ross in Pathogenesis and Treatment of Leukemia

   Chapter 2023
   

8. TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN

   We report herein that TSPAN32 is a key node factor for Philadelphia (Ph ⁺ ) leukemia pathogenesis. We found that TSPAN32 expression was repressed by...

   Qiang Qiu, Yuanyuan Sun, ... Yiguo Hu in Signal Transduction and Targeted Therapy

   Article Open access 01 March 2023
   

9. The importance of personalized medicine in chronic myeloid leukemia management: a narrative review

   Background

   Tyrosine kinase inhibitors (TKIs) are prescribed as a targeted therapy to treat chronic myeloid leukemia patients. A challenge in clinical...

   Erfan Zaker, Negar Nouri, ... Fateme Zare in Egyptian Journal of Medical Human Genetics

   Article Open access 06 April 2023
   

10. Management of Chronic Myeloid Leukemia in Children and Young Adults

    Purpose of Review

    Due to lack of pediatric-specific data, the management of chronic myeloid leukemia (CML) in pediatric, adolescents, and young adults...

    Maegan Ford, Michael Mauro, ... Nobuko Hijiya in Current Hematologic Malignancy Reports

    Article Open access 03 August 2022

11. Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment

    Chronic myeloid leukemia (CML) is very rare during childhood. Tyrosine kinase inhibitors (TKI) provide very good results in terms of survival. The...

    Nihal Karadaş, Şerife Şebnem Önen Göktepe, ... Deniz Yilmaz Karapinar in International Journal of Hematology

    Article 19 November 2022
    

12. Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry

    Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity of the...

    Annamaria Brioli, Elza Lomaia, ... Michael Lauseker in Leukemia

    Article Open access 28 March 2024
    

13. Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia

    Immune thrombocytopenia (ITP) and chronic myeloid leukemia (CML) are rarely observed concurrently. Here we report the case of a patient with ITP who...

    Yuichi Nakamura, Yoshihiro Itoh, Naoki Wakimoto in International Journal of Hematology

    Article Open access 14 November 2022
    

14. Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia

    Background

    Many cytogenetic changes and gene mutations are associated with acute myeloid leukemia (AML) survival outcomes. CD56 is related to poor...

    Tianqi Liang, Zhiyong Peng, ... Chun Chen in BMC Cancer

    Article Open access 21 December 2022
    

15. Outcome prediction of chronic myeloid leukemia (CML) in children

    We evaluated the feasibility of existing risk assessment tools for chronic myeloid leukemia (CML) in children. Fifty-five patients with newly...

    Wing-Yan Leung, Daniel Ka-Leung Cheuk, ... Godfrey Chi-Fung Chan in Annals of Hematology

    Article 01 June 2022
    

16. Droplet digital PCR for genetic mutations monitoring predicts relapse risk in pediatric acute myeloid leukemia

    Multiparameter flow cytometry (MFC)-based minimal residual disease has been a poor predictor of prognosis in children with acute myeloid leukemia...

    **aoyan Chen, Lipeng Liu, ... **aofan Zhu in International Journal of Hematology

    Article 18 July 2022
    

17. EAHP 2020 workshop proceedings, pediatric myeloid neoplasms

    The first section of the bone marrow workshop of the European Association of Haematopathology (EAHP) 2020 Virtual Meeting was dedicated to pediatric...

    R. J. Leguit, A. Orazi, ... M. Ponzoni in Virchows Archiv

    Article Open access 11 July 2022
    

18. Population Pharmacokinetics and Pharmacogenetics Analyses of Dasatinib in Chinese Patients with Chronic Myeloid Leukemia

    Aims

    Dasatinib, a second-generation tyrosine kinase inhibitor of BCR-ABL 1, used for first-line treatment of Philadelphia chromosome-positive chronic...

    Shiyu He, **xia Zhao, ... Qian Jiang in Pharmaceutical Research

    Article 19 September 2023
    

19. Genomic Landscape and Risk Stratification of Acute Myeloid Leukemia

    Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy based on its clinical features, underlying pathogenesis, and treatment...

    Hsin-An Hou in Pathogenesis and Treatment of Leukemia

    Chapter 2023
    

20. Asciminib as a third line option in chronic myeloid leukemia

    Unmet needs remain in the treatment of chronic phase chronic myeloid leukemia (CML) in later lines. Sequential use of tyrosine kinase inhibitors...

    Alessandro Laganà, Emilia Scalzulli, ... Massimo Breccia in International Journal of Hematology

    Article 05 August 2022